Subsequent Events (Details) - Subsequent Event - Teva Pharmaceuticals $ in Millions	1 Months Ended
Jan. 31, 2026 USD ($)
Subsequent Event [Line Items]
Long term funding partnership, maximum commitment	$ 500
Phase 2b
Subsequent Event [Line Items]
Long term funding partnership, maximum commitment	75
Phase 3
Subsequent Event [Line Items]
Long term funding partnership, maximum commitment	$ 425

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration